Cocrystal Pharma (COCP) Cash from Operations (2010 - 2026)
Cocrystal Pharma (COCP) posted Cash from Operations of 2340000.0 for Q1 2026, down 34.17% sequentially from 1744000.0 in Q4 2025, and up 20.38% YoY from 1943827.02 in Q1 2025.
Cocrystal Pharma (COCP) Cash from Operations (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Cash from Operations for 16 years, with the latest figure at 2340000.0 in Q1 2026.
- Quarterly Cash from Operations rose 20.38% year-over-year to 2340000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7601000.0 (up 49.06% YoY) and the FY2025 annual result came in at 8200000.0, up 50.26% from the prior year.
- Cash from Operations eased to 2340000.0 in Q1 2026 per COCP's latest filing, from 1744000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1362000.0 in Q3 2025 and troughed at 8908000.0 in Q3 2022.
- A 5-year average of 3713294.12 and a median of 3326000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 120.9% in 2022, then surged 73.41% in 2025.
- Over 5 years, Cash from Operations stood at 4893000.0 in 2022, then surged by 32.03% to 3326000.0 in 2023, then increased by 4.99% to 3160000.0 in 2024, then soared by 44.81% to 1744000.0 in 2025, then slumped by 34.17% to 2340000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 2340000.0, 1744000.0, and 1362000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - | -2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.52 Mn |
| Jun 30, 2026 | -2.52 Mn |
| Mar 31, 2026 | -2.34 Mn |
| Mar 31, 2026 | -2.34 Mn |
| Dec 31, 2025 | -1.74 Mn |
| Dec 31, 2025 | -1.74 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Dec 31, 2024 | -3.16 Mn |
| Dec 31, 2024 | -3.16 Mn |
| Sep 30, 2024 | -5.12 Mn |
| Sep 30, 2024 | -5.12 Mn |
| Jun 30, 2024 | -3.70 Mn |
| Jun 30, 2024 | -3.70 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Mar 31, 2024 | -4.50 Mn |